Alvotech Clears FDA Hurdle with Voluntary Action Indicated Classification
Event summary
- FDA closed inspection of Alvotech's Reykjavik facility with Voluntary Action Indicated (VAI) classification in July 2026
- Company resubmitted BLAs for AVT05 (biosimilar to Simponi®) and AVT06 (biosimilar to Eylea®)
- FDA accepted BLA submission for AVT16 (biosimilar to Entyvio®) in June 2026
- Alvotech has five approved biosimilars marketed globally, with 13 candidates in development
The big picture
Alvotech's successful FDA inspection closure represents a critical validation of its manufacturing capabilities amid intense biosimilar competition. The company is positioning itself as a cost-effective alternative to branded biologics, with recent BLA resubmissions and submissions signaling continued regulatory engagement. Its fully integrated approach and global partnerships aim to challenge market leaders like Johnson & Johnson and Regeneron in key therapeutic areas.
What we're watching
- Regulatory Progress
- Whether Alvotech can sustain this momentum with upcoming BLA decisions...
- Pipeline Execution
- The pace at which the company advances its 13 biosimilar candidates through development and approval...
- Market Positioning
- How Alvotech's strategic partnerships will impact global market penetration against established competitors...
Related topics